Oncolytic bacteria: A revolutionary approach to cancer therapy
Authors:
- Mohsen A. KhormiMKMohsen A. Khormi
- Saleh M. Al-MaaqarSASaleh M. Al-Maaqar
- Abdulaziz R. Al JohniAJAbdulaziz R. Al Johni
- Nasser A. Al-TayyarNANasser A. Al-Tayyar
- Jafar Abdullah AlhamadJAJafar Abdullah Alhamad
- Abdullah A. GhyathuddinAGAbdullah A. Ghyathuddin
- Zakia AlblawiZAZakia Alblawi
- Sabreen M. BehairySBSabreen M. Behairy
- Mohammed A. AlghamdiMAMohammed A. Alghamdi
- Wael A. AlsubhiWAWael A. Alsubhi
- Mikiyas D. TeklemariamMTMikiyas D. Teklemariam
Open Access
- 1 January 2025
- journal article
- review article
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 20 (1) , 20251076
Abstract
Cancer is one of the most devastating diseases all over the globe, and it is the second worldwide cause of death, exceeded only by cardiovascular diseases. The therapeutic approach to human cancer has evolved significantly and has varied depending on the type and stage of cancer, as well as the general health status of the patient. Despite the advancements in cancer treatment, various challenges persist in the treatment of cancer, including side effects, drug resistance, and incomplete eradication of tumors. The use of oncolytic bacteria (cancer targeting and destroying bacteria) has been identified to have several advantages over the traditional methods of cancer treatment. Several bacterial species have been identified to be used in the treatment of different types of cancers. Oncolytic therapy can be achieved through the use of a naturally occurring and/or genetically modified bacterial species, including Clostridium , Salmonella, Escherichia coli, and Listeria spp. with their toxins, enzymes, biofilms, and secondary metabolites as well as their spores that leads to direct or indirect killing of cancer cells. This review provides some highlights about the biology and therapeutic potential of oncolytic bacteria individually or in combination with other therapeutic approaches against different types of cancers. Besides, the current challenges and future perspectives will be explored.Keywords
This publication has 215 references indexed in Scilit:
- Discovery of Intratumoral Oncolytic Bacteria Toward Targeted Anticancer TheranosticsAdvanced Science, 2023
- Biodegradation and Cytotoxic Effects of Biosurfactants2023
- Biosurfactants as Potential Antitumor Agents2023
- Prebiotics‐Encapsulated Probiotic Spores Regulate Gut Microbiota and Suppress Colon CancerAdvanced Materials, 2020
- Induction of CD4+ and CD8+ anti‐tumor effector T cell responses by bacteria mediated tumor therapyInternational Journal of Cancer, 2015
- Development of novel sophorolipids with improved cytotoxic activity toward MDA‐MB‐231 breast cancer cellsJournal of Molecular Recognition, 2015
- Splenic CD8α+ dendritic cells undergo rapid programming by cytosolic bacteria and inflammation to induce protective CD8+ T‐cell memoryEuropean Journal of Immunology, 2011
- Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimuriumJournal of Cellular Biochemistry, 2009
- Tumor‐targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low‐dose metronomic regimens in a murine melanoma modelInternational Journal of Cancer, 2007
- Coley Toxins — The First Century1990